TNGX Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative prot…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | ||
 Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey Tango Therapeutics stock reaction and recent performance Tango Therapeutics (TNGX) has drawn investor attention after recent trading moves, with the stock closing at US$22.76 on the latest trading day. The price change offers a fresh prompt to reassess the company’s recent performance. Over the past month, Tango Therapeutics stock has fallen about 22%, while the past 3 months show a gain of roughly 13%. Year to date, the stock return is about 155%, and the 1-year total return is about... | ||
 TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus. | ||
 How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% The average of price targets set by Wall Street analysts indicates a potential upside of 49.5% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. | ||
 Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 affordable biotech stocks to buy right now. On June 29, Canaccord Genuity increased its target price on Tango Therapeutics Inc. (NASDAQ:TNGX) from $42 to $46, resulting in more than 53% upside potential. The firm kept a Buy rating on the stock, highlighting further upside from vopimetostat + […] | ||